Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Other Non-Current Liabilities (2021 - 2025)

SAB Biotherapeutics (SABS) has disclosed Other Non-Current Liabilities for 5 consecutive years, with $5.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Non-Current Liabilities fell 11.8% year-over-year to $5.6 million, compared with a TTM value of $5.6 million through Dec 2025, down 11.8%, and an annual FY2025 reading of $5.6 million, down 11.8% over the prior year.
  • Other Non-Current Liabilities was $5.6 million for Q4 2025 at SAB Biotherapeutics, up from $2.4 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $11.8 million in Q4 2023 and bottomed at $8344.0 in Q1 2023.
  • Average Other Non-Current Liabilities over 5 years is $3.8 million, with a median of $3.2 million recorded in 2021.
  • The sharpest move saw Other Non-Current Liabilities tumbled 99.71% in 2023, then skyrocketed 75475.46% in 2024.
  • Year by year, Other Non-Current Liabilities stood at $10.7 million in 2021, then crashed by 97.01% to $320930.0 in 2022, then surged by 3568.79% to $11.8 million in 2023, then crashed by 45.74% to $6.4 million in 2024, then decreased by 11.8% to $5.6 million in 2025.
  • Business Quant data shows Other Non-Current Liabilities for SABS at $5.6 million in Q4 2025, $2.4 million in Q3 2025, and $2.0 million in Q2 2025.